As the tools of imaging technology continue to advance, interventional radiology (IR) has become increasingly therapeutic. Originally used almost exclusively for diagnosis, IR is now used to destroy cancer by the application of heat or cold; block blood vessels that feed tumors; deliver chemotherapy and radiation directly to tumors; and relieve pain caused by cancer that has spread to the spine or other bones.
For patients with invasive bladder cancer, surgical removal of the bladder provides the best chance for a long-term cure. Memorial Sloan-Kettering's surgical techniques have progressed to a point where the vast majority of these patients qualify for a neobladder -- an internal urine-storing pouch attached to the urethra that allows patients to have near-normal urinary control and excellent quality of life after surgery.
The Memorial Sloan-Kettering Center for Cell Engineering has been established to take advantage of the important strides made in the genetic engineering of human cells over the past several years.
Three young investigators who have made major accomplishments in cancer research are the recipients of the 2007 Paul Marks Prize for Cancer Research and will share a $150,000 award.
According to a study published in the Journal of the National Cancer Institute, prostate cancer patients treated by highly experienced surgeons are much more likely to be cancer-free five years after surgery than patients treated by surgeons with less experience.
A recent study conducted at Memorial Sloan-Kettering found that combining MRI screening with a scanning tool known as magnetic resonance spectroscopy can help radiologists in diagnosing breast cancer by producing fewer false-positive results and reducing the number of avoidable biopsies.
New research carried out in the laboratory of Memorial Sloan-Kettering molecular biologist John H.J. Petrini has shed light on one mechanism that helps the cell respond to DNA damage and prevent it from being passed on when the cell divides to create new cells.
A team of scientists led by Memorial Sloan-Kettering investigator Gabriela Chiosis has found that Hsp90 enables the disease process in a group of neurodegenerative disorders marked by the accumulation of the protein Tau.
Philip H. Gutin, a neuro-oncologic surgeon and the incumbent of the Fred Lebow Chair in Neuro-oncology, has been named Chair of Memorial Sloan-Kettering's recently established Department of Neurosurgery.
News@MSKCC provides journalists with news and information from Memorial Sloan-Kettering Cancer Center and is released six times a year.
For more information about these and other potential story ideas, contact Memorial Sloan-Kettering's Department of Public Affairs at: 212-639-3573 or at mediastaff@mskcc.org
